CipherBio is the global community and knowledge hub for life sciences professionals.

$2.01B in Funding Deals and 71 Companies Added

CipherBio Data TeamMarch 1, 2022

CipherBio Weekly Digest: Week of Feb 17 – Feb 23, 2022 $2.01B Deals $274.03M Series A 71 New Companies on CipherBio Sign Up For Your Free Account ➜ Top Deals This Week Minded, New York-based digital health/AI company, raises $25M in Seed round from various investors. Plexium raises $102M in Series A led by BVF […] READ MORE

This Week $2.96B in Life Science Funding

CipherBio Data TeamFebruary 21, 2022

CipherBio Weekly Digest: Week of Feb 10 – Feb 16, 2022 This week our life science funding digest reports $2.77B in deals and $391.90M in Series A. We also added 105 companies and 42 investors to our platform. $2.96B Deals $789.04M Series A $647.7M Later Rounds $900M M&A/IPOs 105 New Companies on CipherBio 42 New Investors […] READ MORE

This Week We Added 70 Companies and 120+ Funding Events

CipherBio Data TeamFebruary 15, 2022

CipherBio Weekly Digest: Week of Feb 3 – Feb 9, 2022 This week’s we bring you news and events about $2.77B in deals, $391.90M in Series A, 70 companies and 29 investors added to our CipherBio platform. $2.77B Deals $391.90M Series A $324.2M Series B $506.3M Later Rounds $1.2B M&A/IPOs 70 New Companies on CipherBio […] READ MORE

This Week in Funding and Clinical Phases

CipherBio Data TeamFebruary 7, 2022

CipherBio Weekly Digest: Week of Jan 27 – Feb 2, 2022 This week’s funding events bring $1.77B in deals, $421M in Series A, 40 new companies added to CipherBio. Furthermore, lot of notable announcements in product clinical phases. $1.77B Deals $421.0M Series A $249.5M Series B $638.3M Later Rounds $240.0M M&A/IPOs 40 New Companies on […] READ MORE

$1.7B in Deals and 136 New Funding Events

CipherBio Data TeamJanuary 31, 2022

CipherBio Weekly Digest: Week of Jan 20 – 26 2022 This week life science growth continues and we report a total of $1.7B in deals and 136 new events, including M&A, IPOs and Funds Raised. Additionally, we added 51 new companies and 20 new investors to our CipherBio PRO platform. $1.7B Deals $318.70M Series A […] READ MORE

This Week $5.74B in Deals and 91 New Life Science Companies

CipherBio Data TeamJanuary 24, 2022

CipherBio Weekly Digest: Week of Jan 13 – 19 2022 This week CipherBio added $5.74B in deals and an incredible 91 new life science companies to our platform. $5.74B Deals $354.8M Series A 91 New Companies Featured Top Investments From seed to acquisition it happened. Avaneer Health announces $50M in Seed funding. […] READ MORE

$11.4B for Cardiovascular Disease in Medical Devices

CipherBio Data TeamJanuary 5, 2022

CipherBio PRO Cardiovascular Disease Insight explores the most targeted condition area for medical devices. The insight includes information on innovative cardiovascular medical device companies that received funding from 2019-2021. Since 2019, 379 VCs have invested $11.4B in 163 companies in life science cardiovascular disease medical devices. 63 of these devices are already on the market. […] READ MORE

81 Digital Therapeutics Companies Received $3.1 Billion From 302 Investors

CipherBio Data TeamSeptember 29, 2021

Digital therapeutics are quickly rising in popularity, with the advancement of technology such as artificial intelligence and machine learning. Digital therapeutics are defined as clinically evaluated software systems used as medical interventions to treat or manage medical conditions. The digital therapeutics field includes Software as a Medical Device (SAMD) which performs as a medical device […] READ MORE

immuno-oncology

183 Immuno-Oncology Companies Raised $46 Billion

CipherBio Data TeamSeptember 14, 2021

Attempts to harness the immune system to fight cancer date back to the late 1800s. It has been less than 40 years since the first of these immuno-oncology therapies demonstrated success and obtained approval. Since then, nearly 40 cancer immunotherapies have received FDA approval. These approved treatments fall into five categories of immunotherapy: cell-based, immunomodulators […] READ MORE

$18 Billion Invested in 135 Cell Therapy Companies

CipherBio Data TeamAugust 18, 2021

Cell therapy was born in the 1930s when Paul Niehans earned the title of “father of cell therapy” by injecting the cells of animal organs into patients with numerous conditions including cancer. Although cell therapy was discovered nearly a century ago, new advances and techniques have caused a large increase in life science cell therapy […] READ MORE

64 Microbiome Biotechs Raise $1.6 Billion in Investments

CipherBio Data TeamJuly 26, 2021

In the last decade, a relatively uncharted field exploded in the life science industry, provoking Forbes to declare the 2010s “The Decade of the Microbiome.” This expansion in the microbiome field was largely due to The National Institutes of Health’s “The Human Microbiome Project,” ending in 2016, which provided significant evidence for the association between […] READ MORE

eye diseases

Life Science Companies Step Up the Fight Against Vision Loss by raising $13B+ from over 300 investors

CipherBio Data TeamJuly 20, 2021

The number of adults at risk for vision loss grew substantially from 2002-2017, from 65 million to 93 million. According to the CDC, more than 4.2 million Americans suffer from low vision or blindness. The leading causes of vision loss are age-related eye diseases such as age-related macular degeneration (AMD), cataract, diabetic retinopathy, and glaucoma. […] READ MORE

Subscribe

Premium Investor Insights